Across TCGA pan-cancer cohorts, HPDL Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HPDL data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HPDL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HPDL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD and UCEC are the cancer types where HPDL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.098	0.682	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.630	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: HPDL tumor-vs-normal RNA expression · all HPDL data types